{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:30:41Z","timestamp":1794011441015,"version":"4.8.0"},"reference-count":216,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2508500"],"award-info":[{"award-number":["2023YFC2508500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404759"],"award-info":[{"award-number":["82404759"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01737-8","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T18:31:33Z","timestamp":1756492293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Recent advances in universal chimeric antigen receptor T cell therapy"],"prefix":"10.1186","volume":"18","author":[{"given":"Ning","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"issue":"26","key":"1737_CR1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR t-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"14","key":"1737_CR2","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR t-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"2","key":"1737_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325\u201332.","journal-title":"Nat Med"},{"issue":"10299","key":"1737_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491\u2013502.","journal-title":"Lancet"},{"key":"1737_CR5","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","DOI":"10.1056\/NEJMoa2024850"},{"issue":"6","key":"1737_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"1737_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/d41573-022-00095-1","volume":"21","author":"AR Saez-Iba\u00f1ez","year":"2022","unstructured":"Saez-Iba\u00f1ez AR, Upadhaya S, Partridge T, Shah M, Correa D, Campbell J. Landscape of cancer cell therapies: trends and real-world data. Nat Rev Drug Discov. 2022;21(9):631\u20132.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"1737_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45956","volume":"5","author":"JH Choe","year":"2022","unstructured":"Choe JH, Abdel-Azim H, Padula WV, Abou-El-Enein M. Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma. JAMA Netw Open. 2022;5(12):e2245956.","journal-title":"JAMA Netw Open"},{"issue":"19","key":"1737_CR9","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1182\/blood.2022016747","volume":"140","author":"S Kambhampati","year":"2022","unstructured":"Kambhampati S, Saumoy M, Schneider Y, Serrao S, Solaimani P, Budde LE, et al. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood. 2022;140(19):2024\u201336.","journal-title":"Blood"},{"key":"1737_CR10","unstructured":"Liu A. CAR-T hype faces infrastructure reality check 2024 [Available from: https:\/\/www.fiercepharma.com\/pharma\/mid-decade-crisis-looms-car-t-cell-therapy."},{"key":"1737_CR11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: major process parameters and next-generation strategies. J Exp Med. 2024. https:\/\/doi.org\/10.1084\/jem.20230903.","journal-title":"J Exp Med"},{"key":"1737_CR12","unstructured":"Liu A. J&J, Legend double CAR-T manufacturing investment to $500M as Carvykti eyes wider myeloma use 2022 [Available from: https:\/\/www.fiercepharma.com\/manufacturing\/legend-jj-double-down-car-t-manufacturing-500m-carvykti-eyes-wider-myeloma-use."},{"issue":"1","key":"1737_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01659-2","volume":"8","author":"Y Wang","year":"2023","unstructured":"Wang Y, Tong C, Lu Y, Wu Z, Guo Y, Liu Y, et al. Characteristics of premanufacture CD8(+)T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(1):409.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"1737_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s13238-017-0411-9","volume":"8","author":"H Li","year":"2017","unstructured":"Li H, Zhao Y. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. Protein Cell. 2017;8(8):573\u201389.","journal-title":"Protein Cell"},{"key":"1737_CR15","unstructured":"Taylor NP. Allogene gets green light for pivotal CAR-T trial, starts industry's first off-the-shelf phase 2 2022 [Available from: https:\/\/www.fiercebiotech.com\/biotech\/allogene-gets-green-light-pivotal-car-t-trial-starts-industrys-first-shelf-phase-2."},{"issue":"24","key":"1737_CR16","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","volume":"119","author":"H Torikai","year":"2012","unstructured":"Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119(24):5697\u2013705.","journal-title":"Blood"},{"issue":"1","key":"1737_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30896-2","volume":"13","author":"S Jo","year":"2022","unstructured":"Jo S, Das S, Williams A, Chretien A-S, Pagliardini T, Le Roy A, et al. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. Nat Commun. 2022;13(1):3453.","journal-title":"Nat Commun"},{"issue":"18","key":"1737_CR18","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","volume":"75","author":"L Poirot","year":"2015","unstructured":"Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, et al. Multiplex Genome-Edited T-cell Manufacturing Platform for \u201cOff-the-Shelf\u201d Adoptive T-cell Immunotherapies. Cancer Res. 2015;75(18):3853\u201364.","journal-title":"Cancer Res"},{"issue":"1","key":"1737_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29668-9","volume":"13","author":"M Sugita","year":"2022","unstructured":"Sugita M, Galetto R, Zong H, Ewing-Crystal N, Trujillo-Alonso V, Mencia-Trinchant N, et al. Allogeneic TCR\u03b1\u03b2 deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nat Commun. 2022;13(1):2227.","journal-title":"Nat Commun"},{"key":"1737_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013","author":"W Qasim","year":"2017","unstructured":"Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aaj2013.","journal-title":"Sci Transl Med"},{"issue":"2","key":"1737_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO, et al. Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023;29(2):422\u20139.","journal-title":"Nat Med"},{"issue":"10","key":"1737_CR22","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","volume":"28","author":"C Sommer","year":"2020","unstructured":"Sommer C, Cheng HY, Nguyen D, Dettling D, Yeung YA, Sutton J, et al. Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery. Mol Ther. 2020;28(10):2237\u201351.","journal-title":"Mol Ther"},{"issue":"15","key":"1737_CR23","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1182\/bloodadvances.2022009397","volume":"7","author":"J Kath","year":"2023","unstructured":"Kath J, Du W, Martini S, Elsallab M, Franke C, Hartmann L, et al. CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products. Blood Advances. 2023;7(15):4124\u201334.","journal-title":"Blood Advances"},{"issue":"7643","key":"1737_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113\u20137.","journal-title":"Nature"},{"key":"1737_CR25","doi-asserted-by":"publisher","first-page":"1052717","DOI":"10.3389\/fimmu.2022.1052717","volume":"13","author":"W Li","year":"2022","unstructured":"Li W, Zhu X, Xu Y, Chen J, Zhang H, Yang Z, et al. Simultaneous editing of TCR, HLA-I\/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection. Front Immunol. 2022;13:1052717.","journal-title":"Front Immunol"},{"issue":"4","key":"1737_CR26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2326-6066.CIR-23-0679","volume":"12","author":"\u00c9 Degagn\u00e9","year":"2024","unstructured":"Degagn\u00e9 \u00c9, Donohoue PD, Roy S, Scherer J, Fowler TW, Davis RT, et al. High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models. Cancer Immunol Res. 2024;12(4):462\u201377.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"1737_CR27","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1002\/eji.202049107","volume":"51","author":"Y Guo","year":"2021","unstructured":"Guo Y, Xu B, Wu Z, Bo J, Tong C, Chen D, et al. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis. Eur J Immunol. 2021;51(10):2513\u201321.","journal-title":"Eur J Immunol"},{"issue":"1","key":"1737_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03586-1","volume":"73","author":"X Chen","year":"2024","unstructured":"Chen X, Tan B, Xing H, Zhao X, Ping Y, Zhang Z, et al. Allogeneic CAR-T cells with of HLA-A\/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies. Cancer Immunol Immunother. 2024;73(1):13.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"1737_CR29","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.stem.2024.06.011","volume":"31","author":"Q Hammer","year":"2024","unstructured":"Hammer Q, Perica K, Mbofung RM, van Ooijen H, Martin KE, Momayyezi P, et al. Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell Stem Cell. 2024;31(9):1376-86.e8.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"1737_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37785-2","volume":"14","author":"X Hu","year":"2023","unstructured":"Hu X, Manner K, DeJesus R, White K, Gattis C, Ngo P, et al. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice. Nat Commun. 2023;14(1):2020.","journal-title":"Nat Commun"},{"issue":"7","key":"1737_CR31","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","volume":"8","author":"Y Kagoya","year":"2020","unstructured":"Kagoya Y, Guo T, Yeung B, Saso K, Anczurowski M, Wang CH, et al. Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy. Cancer Immunol Res. 2020;8(7):926\u201336.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1737_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44786-2","volume":"15","author":"J Ren","year":"2024","unstructured":"Ren J, Liao X, Lewis JM, Chang J, Qu R, Carlson KR, et al. Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-V\u03b22+ T cell malignancy. Nat Commun. 2024;15(1):519.","journal-title":"Nat Commun"},{"issue":"11","key":"1737_CR33","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32(11):995\u20131007.","journal-title":"Cell Res"},{"key":"1737_CR34","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1182\/blood-2024-207322","volume":"144","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhou Y, Zhang M, Fu S, Yu Y, Gao M, et al. A novel generation of anti-CD7 universal CAR-T therapy for patients with relapsed or refractory CD7 positive T-ALL\/Lbl: a phase i clinical trial. Blood. 2024;144:921.","journal-title":"Blood"},{"key":"1737_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041658","author":"C Lonez","year":"2025","unstructured":"Lonez C, Bols\u00e9e J, Huberty F, Nguyen T, Jacques-Hespel C, Anguille S, et al. Clinical proof-of-concept of a non-gene editing technology using miRNA-based shRNA to engineer allogeneic CAR T-cells. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26041658.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1737_CR36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1182\/bloodadvances.2017012823","volume":"2","author":"T Kamiya","year":"2018","unstructured":"Kamiya T, Wong D, Png YT, Campana D. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. Blood Adv. 2018;2(5):517\u201328.","journal-title":"Blood Adv"},{"issue":"15_suppl","key":"1737_CR37","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.2020.38.15_suppl.3032","volume":"38","author":"H Prenen","year":"2020","unstructured":"Prenen H, Dekervel J, Anguille S, Hendlisz A, Michaux A, Sotiropoulou PA, et al. CYAD-101: an innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy. J Clin Oncol. 2020;38(15_suppl):3032.","journal-title":"J Clin Oncol"},{"key":"1737_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008417","author":"K Grauwet","year":"2024","unstructured":"Grauwet K, Berger T, Kann MC, Silva H, Larson R, Leick MB, et al. Stealth transgenes enable CAR-T cells to evade host immune responses. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2023-008417.","journal-title":"J Immunother Cancer"},{"key":"1737_CR39","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-1001","author":"PY Teo","year":"2024","unstructured":"Teo PY, Jung Y, Quach DH, Koh J, Ong RW, Goh A, et al. Overexpression of an engineered SerpinB9 enhances allogeneic T-cell persistence and efficacy. Cancer Immunol Res. 2024. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-1001.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1737_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44176-0","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Fang H, Wang G, Yuan G, Dong R, Luo J, et al. Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells. Nat Commun. 2023;14(1):8491.","journal-title":"Nat Commun"},{"issue":"12","key":"1737_CR41","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41551-024-01282-8","volume":"8","author":"S Menegatti","year":"2024","unstructured":"Menegatti S, Lopez-Cobo S, Sutra Del Galy A, Fuentealba J, Silva L, Perrin L, et al. Ablation of FAS confers allogeneic CD3(-) CAR T cells with resistance to rejection by T cells and natural killer cells. Nat Biomed Eng. 2024;8(12):1651\u201364.","journal-title":"Nat Biomed Eng"},{"key":"1737_CR42","first-page":"979","volume":"29","author":"BB Madison","year":"2022","unstructured":"Madison BB, Patil D, Richter M, Li X, Tong M, Cranert S, et al. Cas-clover is a novel high-fidelity nuclease for safe and robust generation of T(SCM)-enriched allogeneic car-T cells. Mol Ther. 2022;29:979\u201395.","journal-title":"Mol Ther"},{"issue":"1","key":"1737_CR43","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cr.2016.142","volume":"27","author":"X Liu","year":"2017","unstructured":"Liu X, Zhang Y, Cheng C, Cheng AW, Zhang X, Li N, et al. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res. 2017;27(1):154\u20137.","journal-title":"Cell Res"},{"issue":"1","key":"1737_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13007-6","volume":"10","author":"BR Webber","year":"2019","unstructured":"Webber BR, Lonetree CL, Kluesner MG, Johnson MJ, Pomeroy EJ, Diers MD, et al. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat Commun. 2019;10(1):5222.","journal-title":"Nat Commun"},{"issue":"1","key":"1737_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-023-02928-7","volume":"24","author":"V Glaser","year":"2023","unstructured":"Glaser V, Flugel C, Kath J, Du W, Drosdek V, Franke C, et al. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells. Genome Biol. 2023;24(1):89.","journal-title":"Genome Biol"},{"issue":"6","key":"1737_CR46","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood.2022015825","volume":"140","author":"C Diorio","year":"2022","unstructured":"Diorio C, Murray R, Naniong M, Barrera L, Camblin A, Chukinas J, et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood. 2022;140(6):619\u201329.","journal-title":"Blood"},{"issue":"10","key":"1737_CR47","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med. 2023;389(10):899\u2013910.","journal-title":"N Engl J Med"},{"key":"1737_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020. https:\/\/doi.org\/10.1126\/science.aba7365.","journal-title":"Science"},{"key":"1737_CR49","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.2147\/IJN.S424872","volume":"18","author":"KS Allemailem","year":"2023","unstructured":"Allemailem KS, Alsahli MA, Almatroudi A, Alrumaihi F, Al Abdulmonem W, Moawad AA, et al. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR\/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management. Int J Nanomedicine. 2023;18:5531\u201359.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"1737_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13088-3","volume":"10","author":"M Sachdeva","year":"2019","unstructured":"Sachdeva M, Busser BW, Temburni S, Jahangiri B, Gautron AS, Mar\u00e9chal A, et al. Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality. Nat Commun. 2019;10(1):5100.","journal-title":"Nat Commun"},{"issue":"12","key":"1737_CR51","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41551-019-0409-0","volume":"3","author":"K Schober","year":"2019","unstructured":"Schober K, M\u00fcller TR, G\u00f6kmen F, Grassmann S, Effenberger M, Poltorak M, et al. Orthotopic replacement of T-cell receptor \u03b1- and \u03b2-chains with preservation of near-physiological T-cell function. Nat Biomed Eng. 2019;3(12):974\u201384.","journal-title":"Nat Biomed Eng"},{"issue":"7714","key":"1737_CR52","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","volume":"559","author":"TL Roth","year":"2018","unstructured":"Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018;559(7714):405\u20139.","journal-title":"Nature"},{"issue":"Supplement 1","key":"1737_CR53","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2021-147738","volume":"138","author":"A-S Al-Homsi","year":"2021","unstructured":"Al-Homsi A-S, Anguille S, Deeren D, Nishihori T, Meuleman N, Abdul-Hay M, et al. Immunicy-1: targeting BCMA with Cyad-211 to establish proof of concept of an shRNA-based allogeneic CAR T cell therapy platform. Blood. 2021;138(Supplement 1):2817.","journal-title":"Blood"},{"issue":"2","key":"1737_CR54","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;23(2):90\u2013105.","journal-title":"Nat Rev Immunol"},{"key":"1737_CR55","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200839","author":"T Deuse","year":"2021","unstructured":"Deuse T, Hu X, Agbor-Enoh S, Jang MK, Alawi M, Saygi C, et al. The SIRP\u03b1-CD47 immune checkpoint in NK cells. J Exp Med. 2021. https:\/\/doi.org\/10.1084\/jem.20200839.","journal-title":"J Exp Med"},{"key":"1737_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00194","volume":"8","author":"A Takeuchi","year":"2017","unstructured":"Takeuchi A, Saito T. CD4 CTL, a cytotoxic subset of CD4(+) T cells, their differentiation and function. Front Immunol. 2017;8:194.","journal-title":"Front Immunol"},{"issue":"10266","key":"1737_CR57","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020;396(10266):1885\u201394.","journal-title":"Lancet"},{"issue":"11","key":"1737_CR58","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","volume":"9","author":"R Benjamin","year":"2022","unstructured":"Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 2022;9(11):e833\u201343.","journal-title":"Lancet Haematol"},{"issue":"12","key":"1737_CR59","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1093\/intimm\/9.12.1875","volume":"9","author":"FA Bonilla","year":"1997","unstructured":"Bonilla FA, Kokron CM, Swinton P, Geha RS. Targeted gene disruption of murine CD7. Int Immunol. 1997;9(12):1875\u201383.","journal-title":"Int Immunol"},{"issue":"12","key":"1737_CR60","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.4049\/jimmunol.160.12.5749","volume":"160","author":"DM Lee","year":"1998","unstructured":"Lee DM, Staats HF, Sundy JS, Patel DD, Sempowski GD, Scearce RM, et al. Immunologic characterization of CD7-deficient mice. J Immunol. 1998;160(12):5749\u201356.","journal-title":"J Immunol"},{"issue":"4","key":"1737_CR61","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140(4):321\u201334.","journal-title":"Blood"},{"issue":"30","key":"1737_CR62","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J Clin Oncol. 2021;39(30):3340\u201351.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1737_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00822-w","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li C, Du M, Jiang H, Luo W, Tang L, et al. Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer J. 2023;13(1):61.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1737_CR64","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-20-1271","volume":"27","author":"S Li","year":"2021","unstructured":"Li S, Wang X, Yuan Z, Liu L, Luo L, Li Y, et al. Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management. Clin Cancer Res. 2021;27(5):1242\u20136.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1737_CR65","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1038\/s41375-023-02018-4","volume":"37","author":"S Li","year":"2023","unstructured":"Li S, Wang X, Liu L, Liu J, Rao J, Yuan Z, et al. CD7 targeted \u201coff-the-shelf\u201d CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies. Leukemia. 2023;37(11):2176\u201386.","journal-title":"Leukemia"},{"issue":"1","key":"1737_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01427-3","volume":"16","author":"Y Tan","year":"2023","unstructured":"Tan Y, Shan L, Zhao L, Deng B, Ling Z, Zhang Y, et al. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol. 2023;16(1):34.","journal-title":"J Hematol Oncol"},{"key":"1737_CR67","doi-asserted-by":"crossref","unstructured":"Lu P, Zhang X, Yang J, Li J, Qiu L, Gong M, et al. Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia. Blood. 2024.","DOI":"10.1182\/blood.2024024861"},{"key":"1737_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115888","volume":"169","author":"V Moradi","year":"2023","unstructured":"Moradi V, Omidkhoda A, Ahmadbeigi N. The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: An overview of clinical trials. Biomed Pharmacother. 2023;169:115888.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"1737_CR69","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1084\/jem.20171626","volume":"215","author":"A Seki","year":"2018","unstructured":"Seki A, Rutz S. Optimized RNP transfection for highly efficient CRISPR\/Cas9-mediated gene knockout in primary T cells. J Exp Med. 2018;215(3):985\u201397.","journal-title":"J Exp Med"},{"issue":"3","key":"1737_CR70","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/crispr.2019.0074","volume":"3","author":"A Bothmer","year":"2020","unstructured":"Bothmer A, Gareau KW, Abdulkerim HS, Buquicchio F, Cohen L, Viswanathan R, et al. Detection and modulation of DNA translocations during multi-gene genome editing in T cells. CRISPR J. 2020;3(3):177\u201387.","journal-title":"CRISPR J"},{"issue":"6437","key":"1737_CR71","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1126\/science.aav9973","volume":"364","author":"E Zuo","year":"2019","unstructured":"Zuo E, Sun Y, Wei W, Yuan T, Ying W, Sun H, et al. Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science. 2019;364(6437):289\u201392.","journal-title":"Science"},{"issue":"6437","key":"1737_CR72","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1126\/science.aaw7166","volume":"364","author":"S Jin","year":"2019","unstructured":"Jin S, Zong Y, Gao Q, Zhu Z, Wang Y, Qin P, et al. Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice. Science. 2019;364(6437):292\u20135.","journal-title":"Science"},{"issue":"1","key":"1737_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-024-03434-0","volume":"25","author":"L Wu","year":"2024","unstructured":"Wu L, Jiang S, Shi M, Yuan T, Li Y, Huang P, et al. Adenine base editors induce off-target structure variations in mouse embryos and primary human T cells. Genome Biol. 2024;25(1):291.","journal-title":"Genome Biol"},{"issue":"5","key":"1737_CR74","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41556-021-00671-4","volume":"23","author":"L Wang","year":"2021","unstructured":"Wang L, Xue W, Zhang H, Gao R, Qiu H, Wei J, et al. Eliminating base-editor-induced genome-wide and transcriptome-wide off-target mutations. Nat Cell Biol. 2021;23(5):552\u201363.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"1737_CR75","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41587-020-0414-6","volume":"38","author":"JL Doman","year":"2020","unstructured":"Doman JL, Raguram A, Newby GA, Liu DR. Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors. Nat Biotechnol. 2020;38(5):620\u20138.","journal-title":"Nat Biotechnol"},{"key":"1737_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01347","volume":"11","author":"M Rozenbaum","year":"2020","unstructured":"Rozenbaum M, Meir A, Aharony Y, Itzhaki O, Schachter J, Bank I, et al. Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia. Front Immunol. 2020;11:1347.","journal-title":"Front Immunol"},{"issue":"2","key":"1737_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1373","volume":"11","author":"KP Nishimoto","year":"2022","unstructured":"Nishimoto KP, Barca T, Azameera A, Makkouk A, Romero JM, Bai L, et al. Allogeneic CD20-targeted \u03b3\u03b4 T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models. Clin Transl Immunol. 2022;11(2):e1373.","journal-title":"Clin Transl Immunol"},{"key":"1737_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005400","author":"D S\u00e1nchez Mart\u00ednez","year":"2022","unstructured":"S\u00e1nchez Mart\u00ednez D, Tirado N, Mensurado S, Mart\u00ednez-Moreno A, Romec\u00edn P, Guti\u00e9rrez Ag\u00fcera F, et al. Generation and proof-of-concept for allogeneic CD123 CAR-Delta one T (DOT) cells in acute myeloid leukemia. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005400.","journal-title":"J Immunother Cancer"},{"key":"1737_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310873","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wang L, Seo N, Okumura S, Hayashi T, Akahori Y, et al. CAR-modified V\u03b39V\u03b42 T cells propagated using a novel bisphosphonate prodrug for allogeneic adoptive immunotherapy. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241310873.","journal-title":"Int J Mol Sci"},{"key":"1737_CR80","doi-asserted-by":"crossref","unstructured":"Makkouk A, Yang XC, Barca T, Lucas A, Turkoz M, Wong JTS, et al. Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. J Immunother Cancer. 2021;9(12).","DOI":"10.1136\/jitc-2021-003441"},{"key":"1737_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863155","volume":"13","author":"GM Ferry","year":"2022","unstructured":"Ferry GM, Agbuduwe C, Forrester M, Dunlop S, Chester K, Fisher J, et al. A simple and robust single-step method for CAR-V\u03b41 \u03b3\u03b4T cell expansion and transduction for cancer immunotherapy. Front Immunol. 2022;13:863155.","journal-title":"Front Immunol"},{"key":"1737_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031096","author":"R Poels","year":"2021","unstructured":"Poels R, Drent E, Lameris R, Katsarou A, Themeli M, van der Vliet HJ, et al. Preclinical evaluation of invariant natural killer T cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22031096.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"1737_CR83","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1158\/1078-0432.CCR-21-1329","volume":"27","author":"F Simonetta","year":"2021","unstructured":"Simonetta F, Lohmeyer JK, Hirai T, Maas-Bauer K, Alvarez M, Wenokur AS, et al. Allogeneic CAR invariant natural killer T cells exert potent antitumor effects through host CD8 T-cell cross-priming. Clin Cancer Res. 2021;27(21):6054\u201364.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1737_CR84","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s43018-024-00830-0","volume":"5","author":"X Zhou","year":"2024","unstructured":"Zhou X, Wang Y, Dou Z, Delfanti G, Tsahouridis O, Pellegry CM, et al. CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. Nat Cancer. 2024;5(11):1607\u201321.","journal-title":"Nat Cancer"},{"key":"1737_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02226-y","author":"YR Li","year":"2024","unstructured":"Li YR, Zhou Y, Yu J, Kim YJ, Li M, Lee D, et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol. 2024. https:\/\/doi.org\/10.1038\/s41587-024-02226-y.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"1737_CR86","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.ymthe.2024.04.005","volume":"32","author":"YR Li","year":"2024","unstructured":"Li YR, Zhou Y, Yu J, Zhu Y, Lee D, Zhu E, et al. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy. Mol Ther. 2024;32(6):1849\u201374.","journal-title":"Mol Ther"},{"issue":"2, Supplement","key":"1737_CR87","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jtct.2023.12.072","volume":"30","author":"CA Ramos","year":"2024","unstructured":"Ramos CA, Courtney AN, Lulla PD, Hill LC, Kamble RT, Carrum G, et al. Off-the-shelf CD19-specific CAR-NKT cells in patients with relapsed or refractory B-cell malignancies. Transplant Cell Ther. 2024;30(2, Supplement):S41\u20132.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"1737_CR88","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007829","volume":"12","author":"E Moraes Ribeiro","year":"2024","unstructured":"Moraes Ribeiro E, Secker K-A, Nitulescu A-M, Schairer R, Keppeler H, Wesle A, et al. PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity. J Immunother Cancer. 2024;12(1):e007829.","journal-title":"J Immunother Cancer"},{"issue":"70","key":"1737_CR89","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl3642","volume":"7","author":"D Vasic","year":"2022","unstructured":"Vasic D, Lee JB, Leung Y, Khatri I, Na Y, Abate-Daga D, et al. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities. Sci Immunol. 2022;7(70):eabl3642.","journal-title":"Sci Immunol"},{"key":"1737_CR90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007277","author":"KK Fang","year":"2023","unstructured":"Fang KK, Lee J, Khatri I, Na Y, Zhang L. Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007277.","journal-title":"J Immunother Cancer"},{"key":"1737_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102516","volume":"70","author":"X Xiao","year":"2024","unstructured":"Xiao X, Liu H, Qiu X, Chen P, Li X, Wang D, et al. CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study. EClinicalMedicine. 2024;70:102516.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"1737_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200814","volume":"32","author":"DH Quach","year":"2024","unstructured":"Quach DH, Ganesh HR, Briones YD, Nouraee N, Ma A, Hadidi YF, et al. Rejection resistant CD30.CAR-modified Epstein-Barr virus-specific T cells as an off-the-shelf platform for CD30(+) lymphoma. Mol Ther Oncol. 2024;32(2):200814.","journal-title":"Mol Ther Oncol"},{"key":"1737_CR93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003461","author":"X Wang","year":"2022","unstructured":"Wang X, Urak R, Walter M, Guan M, Han T, Vyas V, et al. Large-scale manufacturing and characterization of CMV-CD19CAR T cells. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003461.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"1737_CR94","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.stem.2022.02.009","volume":"29","author":"Z Wang","year":"2022","unstructured":"Wang Z, McWilliams-Koeppen HP, Reza H, Ostberg JR, Chen W, Wang X, et al. 3D-organoid culture supports differentiation of human CAR(+) iPSCs into highly functional CAR T cells. Cell Stem Cell. 2022;29(4):515-27.e8.","journal-title":"Cell Stem Cell"},{"key":"1737_CR95","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2021-149095","volume":"138","author":"MA Wallet","year":"2021","unstructured":"Wallet MA, Nishimura T, Del Casale C, Lebid A, Salantes B, Santostefano K, et al. Induced pluripotent stem cell-derived gamma delta CAR-T cells for cancer immunotherapy. Blood. 2021;138:2771.","journal-title":"Blood"},{"issue":"1","key":"1737_CR96","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.stem.2024.10.004","volume":"32","author":"R Jing","year":"2025","unstructured":"Jing R, Falchetti M, Han T, Najia M, Hensch LT, Meader E, et al. Maturation and persistence of CAR T cells derived from human pluripotent stem cells via chemical inhibition of G9a\/GLP. Cell Stem Cell. 2025;32(1):71-85.e5.","journal-title":"Cell Stem Cell"},{"key":"1737_CR97","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008656","author":"N Ruggeri Barbaro","year":"2024","unstructured":"Ruggeri Barbaro N, Drashansky T, Tess K, Djedaini M, Hariri R, He S, et al. Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2023-008656.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1737_CR98","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41423-020-0515-7","volume":"18","author":"Y Xu","year":"2021","unstructured":"Xu Y, Xiang Z, Alnaggar M, Kouakanou L, Li J, He J, et al. Allogeneic v\u03b39v\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2021;18(2):427\u201339.","journal-title":"Cell Mol Immunol"},{"issue":"16_suppl","key":"1737_CR99","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1200\/JCO.2022.40.16_suppl.7509","volume":"40","author":"SS Neelapu","year":"2022","unstructured":"Neelapu SS, Hamadani M, Miklos DB, Holmes H, Hinkle J, Kennedy-Wilde J, et al. A phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma delta (\u03b3\u03b4) T cells in adults with B-cell malignancies. J Clin Oncol. 2022;40(16_suppl):7509.","journal-title":"J Clin Oncol"},{"key":"1737_CR100","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1182\/blood-2023-181919","volume":"142","author":"MA Moreno","year":"2023","unstructured":"Moreno MA, Kennedy-Wilde J, Wrong AD, Jahchan N, Galimi F, Ye Y, et al. Expansion, persistence and pharmacodynamic profile of ADI-001, a first-in-class allogeneic CD20-targeted CAR gamma delta T cell therapy, in patients with relapsed\/refractory aggressive B-cell non-Hodgkin\u2019s lymphoma. Blood. 2023;142:3478.","journal-title":"Blood"},{"key":"1737_CR101","unstructured":"Bio A. Building a broad pipeline in autoimmune diseases & cancer 2024 [Available from: https:\/\/www.adicetbio.com\/pipeline\/."},{"key":"1737_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1299044","volume":"15","author":"LB Nabors","year":"2024","unstructured":"Nabors LB, Lamb LS, Goswami T, Rochlin K, Youngblood SL. Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified \u03b3\u03b4 t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions. Front Immunol. 2024;15:1299044.","journal-title":"Front Immunol"},{"issue":"3","key":"1737_CR103","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","volume":"20","author":"S Mensurado","year":"2023","unstructured":"Mensurado S, Blanco-Dom\u00ednguez R, Silva-Santos B. The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy. Nat Rev Clin Oncol. 2023;20(3):178\u201391.","journal-title":"Nat Rev Clin Oncol"},{"key":"1737_CR104","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011704","author":"KP Nishimoto","year":"2025","unstructured":"Nishimoto KP, Lamture G, Chanthery Y, Teague AG, Verma Y, Au M, et al. ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignancies. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-011704.","journal-title":"J Immunother Cancer"},{"key":"1737_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00384","volume":"9","author":"BJ Wolf","year":"2018","unstructured":"Wolf BJ, Choi JE, Exley MA. Novel approaches to exploiting invariant NKT cells in cancer immunothe rapy. Front Immunol. 2018;9:384.","journal-title":"Front Immunol"},{"issue":"8","key":"1737_CR106","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood.2022016201","volume":"141","author":"AN Courtney","year":"2023","unstructured":"Courtney AN, Tian G, Metelitsa LS. Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy. Blood. 2023;141(8):869\u201376.","journal-title":"Blood"},{"issue":"23","key":"1737_CR107","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","volume":"25","author":"X Xu","year":"2019","unstructured":"Xu X, Huang W, Heczey A, Liu D, Guo L, Wood M, et al. NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma. Clin Cancer Res. 2019;25(23):7126\u201338.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1737_CR108","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","volume":"29","author":"A Heczey","year":"2023","unstructured":"Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023;29(6):1379\u201388.","journal-title":"Nat Med"},{"issue":"74","key":"1737_CR109","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn6563","volume":"7","author":"G Delfanti","year":"2022","unstructured":"Delfanti G, Cortesi F, Perini A, Antonini G, Azzimonti L, de Lalla C, et al. TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells. Sci Immunol. 2022;7(74):eabn6563.","journal-title":"Sci Immunol"},{"issue":"7","key":"1737_CR110","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1158\/1078-0432.CCR-18-2291","volume":"25","author":"JB Lee","year":"2019","unstructured":"Lee JB, Kang H, Fang L, D\u2019Souza C, Adeyi O, Zhang L. Developing allogeneic double-negative T cells as a novel off-the-shelf adoptive cellular therapy for cancer. Clin Cancer Res. 2019;25(7):2241\u201353.","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"1737_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-141505","volume":"136","author":"T Baolin","year":"2020","unstructured":"Baolin T, Lee J, Cheng S, Yao W, Wang D, Tu M, et al. Safety and efficacy of ex vivo expanded healthy donor-derived double negative T cells for the treatment of AML relapsed after allogeneic stem cell transplantation: a first in-human phase I\/IIa clinical trial. Blood. 2020;136(Supplement 1):1\u20132.","journal-title":"Blood"},{"issue":"7","key":"1737_CR112","doi-asserted-by":"publisher","first-page":"E264","DOI":"10.1002\/ajh.26564","volume":"97","author":"B Tang","year":"2022","unstructured":"Tang B, Lee JB, Cheng S, Pan T, Yao W, Wang D, et al. Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: a first-in-human phase I study. Am J Hematol. 2022;97(7):E264-7.","journal-title":"Am J Hematol"},{"issue":"2","key":"1737_CR113","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/1078-0432.CCR-17-2228","volume":"24","author":"J Lee","year":"2018","unstructured":"Lee J, Minden MD, Chen WC, Streck E, Chen B, Kang H, et al. Allogeneic human double negative t cells as a novel immunotherapy for acute myeloid leukemia and its underlying mechanisms. Clin Cancer Res. 2018;24(2):370\u201382.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1737_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0507-2","volume":"7","author":"J Yao","year":"2019","unstructured":"Yao J, Ly D, Dervovic D, Fang L, Lee JB, Kang H, et al. Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15. J Immunother Cancer. 2019;7(1):17.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"1737_CR115","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/bmt.2016.17","volume":"51","author":"RJ O\u2019Reilly","year":"2016","unstructured":"O\u2019Reilly RJ, Prockop S, Hasan AN, Koehne G, Doubrovina E. Virus-specific T-cell banks for \u201coff the shelf\u201d adoptive therapy of refractory infections. Bone Marrow Transplant. 2016;51(9):1163\u201372.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"1737_CR116","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1737_CR117","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","volume":"29","author":"T Pfeiffer","year":"2023","unstructured":"Pfeiffer T, Tzannou I, Wu M, Ramos C, Sasa G, Martinez C, et al. Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting. Clin Cancer Res. 2023;29(2):324\u201330.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1737_CR118","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell. 2025;43(4):665\u201379.","journal-title":"Cancer Cell"},{"key":"1737_CR119","doi-asserted-by":"crossref","unstructured":"Xiang J, Devenport JM, Carter AJ, Staser KW, Kim MY, J ON, et al. An \"off-the-shelf\" CD2 universal CAR-T therapy for T-cell malignancies. Leukemia. 2023;37(12):2448\u201356.","DOI":"10.1038\/s41375-023-02039-z"},{"issue":"1","key":"1737_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30860-0","volume":"13","author":"MY Kim","year":"2022","unstructured":"Kim MY, Jayasinghe R, Devenport JM, Ritchey JK, Rettig MP, O\u2019Neal J, et al. A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity. Nat Commun. 2022;13(1):3296.","journal-title":"Nat Commun"},{"issue":"7","key":"1737_CR121","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1016\/j.ymthe.2024.05.013","volume":"32","author":"CM Hull","year":"2024","unstructured":"Hull CM, Larcombe-Young D, Mazza R, George M, Davies DM, Schurich A, et al. Granzyme B-activated IL18 potentiates \u03b1\u03b2 and \u03b3\u03b4 CAR T cell immunotherapy in a tumor-dependent manner. Mol Ther. 2024;32(7):2373\u201392.","journal-title":"Mol Ther"},{"issue":"9","key":"1737_CR122","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","volume":"18","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18(9):2188\u201398.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"1737_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0806-7","volume":"7","author":"BD Choi","year":"2019","unstructured":"Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer. 2019;7(1):304.","journal-title":"J Immunother Cancer"},{"key":"1737_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216660","volume":"585","author":"Q Lu","year":"2024","unstructured":"Lu Q, Yang D, Li H, Zhu Z, Zhang Z, Chen Y, et al. Delivery of CD47-SIRP\u03b1 checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma. Cancer Lett. 2024;585:216660.","journal-title":"Cancer Lett"},{"issue":"17","key":"1737_CR125","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206856","volume":"10","author":"SW Huang","year":"2023","unstructured":"Huang SW, Pan CM, Lin YC, Chen MC, Chen Y, Jan CI, et al. BiTE-Secreting CAR-\u03b3\u03b4T as a Dual Targeting Strategy for the Treatment of Solid Tumors. Adv Sci (Weinh). 2023;10(17):e2206856.","journal-title":"Adv Sci (Weinh)"},{"issue":"12","key":"1737_CR126","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood.2020005185","volume":"136","author":"D Stenger","year":"2020","unstructured":"Stenger D, Stief TA, Kaeuferle T, Willier S, Rataj F, Schober K, et al. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR. Blood. 2020;136(12):1407\u201318.","journal-title":"Blood"},{"issue":"11","key":"1737_CR127","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4\u20131BB costimulatory domains. Nat Rev Clin Oncol. 2021;18(11):715\u201327.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1737_CR128","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36(4):346\u201351.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"1737_CR129","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","volume":"10","author":"J Zhou","year":"2019","unstructured":"Zhou J, Jin L, Wang F, Zhang Y, Liu B, Zhao T. Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects. Protein Cell. 2019;10(10):764\u20139.","journal-title":"Protein Cell"},{"key":"1737_CR130","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192203","author":"E Lanitis","year":"2021","unstructured":"Lanitis E, Rota G, Kosti P, Ronet C, Spill A, Seijo B, et al. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J Exp Med. 2021. https:\/\/doi.org\/10.1084\/jem.20192203.","journal-title":"J Exp Med"},{"key":"1737_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.609421","volume":"12","author":"D Duan","year":"2021","unstructured":"Duan D, Wang K, Wei C, Feng D, Liu Y, He Q, et al. The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma. Front Immunol. 2021;12:609421.","journal-title":"Front Immunol"},{"key":"1737_CR132","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Garc\u00eda L, G. S\u00e1nchez E, Ivanova M, Pastora K, Alc\u00e1ntara-S\u00e1nchez C, Garc\u00eda-Mart\u00ednez J, et al. Choosing T-cell sources determines CAR-T cell activity in neuroblastoma. Front Immunol. 2024;15.","DOI":"10.3389\/fimmu.2024.1375833"},{"issue":"6","key":"1737_CR133","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","volume":"2","author":"L Biasco","year":"2021","unstructured":"Biasco L, Izotova N, Rivat C, Ghorashian S, Richardson R, Guvenel A, et al. Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nat Cancer. 2021;2(6):629\u201342.","journal-title":"Nat Cancer"},{"key":"1737_CR134","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1209","author":"Y Yang","year":"2017","unstructured":"Yang Y, Kohler ME, Chien CD, Sauter CT, Jacoby E, Yan C, et al. TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aag1209.","journal-title":"Sci Transl Med"},{"key":"1737_CR135","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1786","author":"EW Weber","year":"2021","unstructured":"Weber EW, Parker KR, Sotillo E, Lynn RC, Anbunathan H, Lattin J, et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science. 2021. https:\/\/doi.org\/10.1126\/science.aba1786.","journal-title":"Science"},{"key":"1737_CR136","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz0868","author":"HT Nia","year":"2020","unstructured":"Nia HT, Munn LL, Jain RK. Physical traits of cancer. Science. 2020. https:\/\/doi.org\/10.1126\/science.aaz0868.","journal-title":"Science"},{"issue":"12","key":"1737_CR137","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/s41423-024-01228-9","volume":"21","author":"R Zheng","year":"2024","unstructured":"Zheng R, Shen K, Liang S, Lyu Y, Zhang S, Dong H, et al. Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors. Cell Mol Immunol. 2024;21(12):1491\u2013504.","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"1737_CR138","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/eji.201948457","volume":"50","author":"G Liu","year":"2020","unstructured":"Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y, et al. Cxcr2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol. 2020;50(5):712\u201324.","journal-title":"Eur J Immunol"},{"issue":"4","key":"1737_CR139","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03648-y","volume":"73","author":"Z Dai","year":"2024","unstructured":"Dai Z, Lin X, Wang X, Zou X, Yan Y, Wang R, et al. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma. Cancer Immunol Immunother. 2024;73(4):61.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"1737_CR140","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"1737_CR141","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H. Regulatory t cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16(6):356\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1737_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02079-8","volume":"23","author":"X Xia","year":"2024","unstructured":"Xia X, Yang Z, Lu Q, Liu Z, Wang L, Du J, et al. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer. 2024;23(1):175.","journal-title":"Mol Cancer"},{"key":"1737_CR143","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003737","author":"H Chen","year":"2022","unstructured":"Chen H, Yang Y, Deng Y, Wei F, Zhao Q, Liu Y, et al. Delivery of CD47 blocker SIRP\u03b1-Fc by CAR-T cells enhances antitumor efficacy. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003737.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1737_CR144","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ccell.2022.05.004","volume":"40","author":"K Kersten","year":"2022","unstructured":"Kersten K, Hu KH, Combes AJ, Samad B, Harwin T, Ray A, et al. Spatiotemporal co-dependency between macrophages and exhausted CD8(+) T cells in cancer. Cancer Cell. 2022;40(6):624-38.e9.","journal-title":"Cancer Cell"},{"issue":"6","key":"1737_CR145","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","volume":"20","author":"DV Sawant","year":"2019","unstructured":"Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, et al. Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019;20(6):724\u201335.","journal-title":"Nat Immunol"},{"issue":"1","key":"1737_CR146","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-022-01255-x","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Si X, Shao M, Teng X, Xiao G, Huang H. Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells. J Hematol Oncol. 2022;15(1):38.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1737_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01646-7","volume":"8","author":"Y Wang","year":"2023","unstructured":"Wang Y, Han J, Wang D, Cai M, Xu Y, Hu Y, et al. Anti-PD-1 antibody armored \u03b3\u03b4 T cells enhance anti-tumor efficacy in ovarian cancer. Signal Transduct Target Ther. 2023;8(1):399.","journal-title":"Signal Transduct Target Ther"},{"key":"1737_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121341","volume":"281","author":"Y Luo","year":"2022","unstructured":"Luo Y, Chen Z, Sun M, Li B, Pan F, Ma A, et al. IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy. Biomaterials. 2022;281:121341.","journal-title":"Biomaterials"},{"issue":"1","key":"1737_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20599-x","volume":"12","author":"G Agliardi","year":"2021","unstructured":"Agliardi G, Liuzzi AR, Hotblack A, De Feo D, N\u00fa\u00f1ez N, Stowe CL, et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 2021;12(1):444.","journal-title":"Nat Commun"},{"key":"1737_CR150","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006239","author":"M Zannikou","year":"2023","unstructured":"Zannikou M, Duffy JT, Levine RN, Seblani M, Liu Q, Presser A, et al. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-006239.","journal-title":"J Immunother Cancer"},{"issue":"Supplement 1","key":"1737_CR151","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1182\/blood-2022-160219","volume":"140","author":"CM Stewart","year":"2022","unstructured":"Stewart CM, Cox MJ, Sakemura RL, Ogbodo EJ, Can I, Manriquez-Roman C, et al. Identification of IL-4 as a key regulator of CAR T-cell exhaustion using functional genomics and correlates of the Zuma-1 clinical trial. Blood. 2022;140(Supplement 1):4536\u20137.","journal-title":"Blood"},{"key":"1737_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115740","volume":"168","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Farooq MA, Ajmal I, He C, Gao Y, Guo D, et al. Co-expression of IL-4\/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment. Biomed Pharmacother. 2023;168:115740.","journal-title":"Biomed Pharmacother"},{"key":"1737_CR153","doi-asserted-by":"crossref","unstructured":"Wellhausen N, O'Connell RP, Lesch S, Engel NW, Rennels AK, Gonzales D, et al. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Sci Transl Med. 2023;15(714):eadi1145.","DOI":"10.1126\/scitranslmed.adi1145"},{"issue":"8","key":"1737_CR154","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, et al. Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J Clin Invest. 2016;126(8):3036\u201352.","journal-title":"J Clin Invest"},{"issue":"5","key":"1737_CR155","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat Med. 2024;30(5):1320\u20139.","journal-title":"Nat Med"},{"issue":"17","key":"1737_CR156","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.7150\/thno.43991","volume":"10","author":"M Yang","year":"2020","unstructured":"Yang M, Tang X, Zhang Z, Gu L, Wei H, Zhao S, et al. Tandem CAR-T cells targeting CD70 and B7\u2013H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics. 2020;10(17):7622\u201334.","journal-title":"Theranostics"},{"issue":"9","key":"1737_CR157","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi K, Du H, Xu Y, Shou P, Zhou X, Fuc\u00e1 G, et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer. 2021;2(9):904\u201318.","journal-title":"Nat Cancer"},{"issue":"9","key":"1737_CR158","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37(9):1049\u201358.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"1737_CR159","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1002\/ijc.32618","volume":"146","author":"R Arriga","year":"2020","unstructured":"Arriga R, Caratelli S, Lanzilli G, Ottaviani A, Cenciarelli C, Sconocchia T, et al. CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab. Int J Cancer. 2020;146(9):2531\u20138.","journal-title":"Int J Cancer"},{"key":"1737_CR160","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003752","author":"YC Kuo","year":"2022","unstructured":"Kuo YC, Kuo CF, Jenkins K, Hung AF, Chang WC, Park M, et al. Antibody-based redirection of universal fabrack-CAR T cells selectively kill antigen bearing tumor cells. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003752.","journal-title":"J Immunother Cancer"},{"key":"1737_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094920","author":"N Mitwasi","year":"2022","unstructured":"Mitwasi N, Arndt C, Loureiro LR, Kegler A, Fasslrinner F, Berndt N, et al. Targeting CD10 on B-cell leukemia using the universal CAR T-cell platform (UniCAR). Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23094920.","journal-title":"Int J Mol Sci"},{"key":"1737_CR162","first-page":"408","volume":"17","author":"S Loff","year":"2020","unstructured":"Loff S, Dietrich J, Meyer JE, Riewaldt J, Spehr J, von Bonin M, et al. Rapidly switchable universal CAR-T cells for treatment of CD123-positive leukemia. Mol Ther. 2020;17:408\u201320.","journal-title":"Mol Ther"},{"issue":"1","key":"1737_CR163","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1945804","volume":"10","author":"JE Meyer","year":"2021","unstructured":"Meyer JE, Loff S, Dietrich J, Spehr J, Jurado Jim\u00e9nez G, von Bonin M, et al. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML. Oncoimmunology. 2021;10(1):1945804.","journal-title":"Oncoimmunology"},{"issue":"5","key":"1737_CR164","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1021\/acs.bioconjchem.4c00050","volume":"35","author":"T Abudureheman","year":"2024","unstructured":"Abudureheman T, Zhou H, Yang LT, Huang XS, Jing JJ, Duan CW, et al. Construction of switch modules for CAR-T cell treatment using a site-specific conjugation system. Bioconjug Chem. 2024;35(5):604\u201315.","journal-title":"Bioconjug Chem"},{"issue":"8","key":"1737_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2022.167513","volume":"434","author":"L Rong","year":"2022","unstructured":"Rong L, Lim RM, Yin X, Tan L, Yang JH, Xie J. Site-specific dinitrophenylation of single-chain antibody fragments for redirecting a universal CAR-T cell against cancer antigens. J Mol Biol. 2022;434(8):167513.","journal-title":"J Mol Biol"},{"issue":"34","key":"1737_CR166","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1038\/s41388-022-02416-5","volume":"41","author":"H Peng","year":"2022","unstructured":"Peng H, Nerreter T, Mestermann K, Wachter J, Chang J, Hudecek M, et al. ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene. 2022;41(34):4104\u201314.","journal-title":"Oncogene"},{"issue":"5","key":"1737_CR167","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.apsb.2023.02.004","volume":"13","author":"W Zhu","year":"2023","unstructured":"Zhu W, Wang Y, Lv L, Wang H, Shi W, Liu Z, et al. Universal chimeric Fc\u03b3 receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy. Acta Pharm Sin B. 2023;13(5):2071\u201385.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"1737_CR168","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01246-y","volume":"15","author":"Z Sun","year":"2022","unstructured":"Sun Z, Li R, Shen Y, Tan S, Ding N, Xu R, et al. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors. J Hematol Oncol. 2022;15(1):29.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1737_CR169","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41551-023-01102-5","volume":"8","author":"AV Stepanov","year":"2024","unstructured":"Stepanov AV, Xie J, Zhu Q, Shen Z, Su W, Kuai L, et al. Control of the antitumour activity and specificity of CAR T cells via organic adapters covalently tethering the CAR to tumour cells. Nat Biomed Eng. 2024;8(5):529\u201343.","journal-title":"Nat Biomed Eng"},{"issue":"10","key":"1737_CR170","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1021\/acssynbio.3c00320","volume":"12","author":"M Kvorjak","year":"2023","unstructured":"Kvorjak M, Ruffo E, Tivon Y, So V, Parikh A, Deiters A, et al. Conditional control of universal CAR T cells by cleavable off-switch adaptors. ACS Synth Biol. 2023;12(10):2996\u20133007.","journal-title":"ACS Synth Biol"},{"key":"1737_CR171","unstructured":"Administration USFaD. Guidance for Industry: Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products 2021 [Available from: https:\/\/www.fda.gov\/media\/156896\/download."},{"key":"1737_CR172","unstructured":"Agency EM. Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells 2021 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-non-clinical-and-clinical-aspects-medicinal-products-containing-genetically-modified-cells-revision-1_en.pdf."},{"key":"1737_CR173","unstructured":"China NMPAo. Technical Guiding Principles for Clinical Trials of Immune Cell Therapy Products (Trial) 2021 [Available from: https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/1936d1c9006ccce2251702221f063b1c."},{"key":"1737_CR174","unstructured":"China NMPAo. Technical Guiding Principles for Clinical Pharmacology Studies of Cell Therapy Products (Trial) 2024 [Available from: https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/6eda537828949a51a4a56e341423f7c3."},{"key":"1737_CR175","unstructured":"China NMPAo. Technical Guiding Principles for Non-clinical Research and Evaluation of Gene-Modified Cell Therapy Products (Trial). 2021."},{"issue":"2","key":"1737_CR176","volume":"73","author":"EH Tan","year":"2025","unstructured":"Tan EH, Aljurf M, Hussain F, Chabannon C, Worel N, Weisdorf D, et al. Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: a worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT). Curr Res Transl Med. 2025;73(2):103515.","journal-title":"Curr Res Transl Med"},{"key":"1737_CR177","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01933","author":"FL Locke","year":"2025","unstructured":"Locke FL, Munoz JL, Tees MT, Lekakis LJ, de Vos S, Nath R, et al. Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel\/ALLO-501 in relapsed\/refractory large B-cell lymphoma: phase i experience from the ALPHA2\/ALPHA clinical studies. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO-24-01933.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1737_CR178","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","volume":"26","author":"SP Iyer","year":"2025","unstructured":"Iyer SP, Sica RA, Ho PJ, Prica A, Zain J, Foss FM, et al. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Lancet Oncol. 2025;26(1):110\u201322.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1737_CR179","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41591-024-03282-2","volume":"31","author":"J Pan","year":"2025","unstructured":"Pan J, Tan Y, Shan L, Seery S, Deng B, Ling Z, et al. Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial. Nat Med. 2025;31(1):126\u201336.","journal-title":"Nat Med"},{"key":"1737_CR180","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0102","author":"SK Pal","year":"2024","unstructured":"Pal SK, Tran B, Haanen J, Hurwitz ME, Sacher A, Tannir NM, et al. CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma. Cancer Discov. 2024. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0102.","journal-title":"Cancer Discov"},{"issue":"3","key":"1737_CR181","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41591-024-03449-x","volume":"31","author":"C Quintarelli","year":"2025","unstructured":"Quintarelli C, Del Bufalo F, De Ioris MA, Guercio M, Algeri M, Pagliara D, et al. Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma. Nat Med. 2025;31(3):849\u201360.","journal-title":"Nat Med"},{"issue":"16_suppl","key":"1737_CR182","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1200\/JCO.2023.41.16_suppl.2043","volume":"41","author":"X Shang","year":"2023","unstructured":"Shang X. An exploratory clinical trial on intra-lumbar injection of B7H3-specific allogeneic universal CAR-T cells in patients with recurrent high-grade gliomas. J Clin Oncol. 2023;41(16_suppl):2043.","journal-title":"J Clin Oncol"},{"key":"1737_CR183","doi-asserted-by":"crossref","unstructured":"Dholaria B, Kocoglu MH, Kin A, Asch AS, Ramakrishnan A, Bachier C, et al. Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed \/ Refractory Multiple Myeloma (RRMM). Blood. 2023;142(Supplement 1):3479-.","DOI":"10.1182\/blood-2023-182430"},{"key":"1737_CR184","doi-asserted-by":"crossref","unstructured":"Lonez C, Bolsee J, Huberty F, Nguyen T, Jacques-Hespel C, Demoulin B, et al. 285\u2005Proof-of-concept of a non-gene editing technology using shRNA down-regulation to engineer and optimize CAR T-cell functionality. Journal for ImmunoTherapy of Cancer. 2023;11(Suppl 1):A326-A.","DOI":"10.1136\/jitc-2023-SITC2023.0285"},{"issue":"6","key":"1737_CR185","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41375-024-02251-5","volume":"38","author":"W Lu","year":"2024","unstructured":"Lu W, Lyu H, Xiao X, Bai X, Zhang M, Wang J, et al. Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia. 2024;38(6):1419\u201322.","journal-title":"Leukemia"},{"key":"1737_CR186","volume":"67","author":"Y Luo","year":"2024","unstructured":"Luo Y, Gao L, Liu J, Yang L, Wang L, Lai X, et al. Donor-derived anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial. EClin Med. 2024;67:102377.","journal-title":"EClin Med"},{"issue":"Supplement 1","key":"1737_CR187","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1182\/blood-2023-180753","volume":"142","author":"S Shahid","year":"2023","unstructured":"Shahid S, Flynn GC, Mauguen A, Bieler J, Prockop SE, Scaradavou A, et al. Long term follow-up after treatment with allogeneic off-the-shelf CAR T cell therapy for relapsed or refractory B-cell malignancies. Blood. 2023;142(Supplement 1):3476.","journal-title":"Blood"},{"key":"1737_CR188","doi-asserted-by":"crossref","unstructured":"HU Y, Wei G, Fu S, Xiao P, Feng J, Zhang M, et al. Intracellular Retention of Tcr\u03b1\u03b2\/CD3 to Generate Novel Allogeneic CAR-T Cells (ThisCART19A) with Enhanced Antitumor Potency for Treating B-ALL. Blood. 2023;142(Supplement 1):2111-.","DOI":"10.1182\/blood-2023-189052"},{"key":"1737_CR189","doi-asserted-by":"crossref","unstructured":"Xiao X, Lei W, Jiang H, Qiu X, Li X, Chen P, et al. A phase 1 study of RJMty19: anti-CD19 humanized CAR-engineered allogeneic double negative T cells in adults with B-cell non-Hodgkin\u2019s lymphoma. Blood. 2023;142(Supplement 1):2094\u20132094.","DOI":"10.1182\/blood-2023-189149"},{"issue":"Supplement 1","key":"1737_CR190","doi-asserted-by":"publisher","first-page":"10303","DOI":"10.1182\/blood-2022-166432","volume":"140","author":"JP McGuirk","year":"2022","unstructured":"McGuirk JP, Tam CS, Kr\u00f6ger N, Riedell PA, Murthy HS, Ho PJ, et al. CTX110 allogeneic CRISPR-Cas9-engineered CAR T cells in patients (Pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): results from the phase 1 dose escalation carbon study. Blood. 2022;140(Supplement 1):10303\u20136.","journal-title":"Blood"},{"issue":"9","key":"1737_CR191","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.clml.2020.04.007","volume":"20","author":"J Hua","year":"2020","unstructured":"Hua J, Zhang J, Wu X, Zhou L, Bao X, Han Y, et al. Allogeneic donor-derived anti-CD19 CAR T cell is a promising therapy for relapsed\/refractory B-ALL after allogeneic hematopoietic stem-cell transplantation. Clin Lymphoma Myeloma Leuk. 2020;20(9):610\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"1737_CR192","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34(10):1112\u201321.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1737_CR193","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","volume":"122","author":"CR Cruz","year":"2013","unstructured":"Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122(17):2965\u201373.","journal-title":"Blood"},{"issue":"25","key":"1737_CR194","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","volume":"122","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(25):4129\u201339.","journal-title":"Blood"},{"key":"1737_CR195","doi-asserted-by":"crossref","unstructured":"Li S, Wang X, Yuan Z, Liu L, Li Y, Liu J, et al. Early results of a safety and efficacy study of allogeneic TruUCAR\u2122 GC502 in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (r\/r B-ALL). Cancer Research. 2022;82(12).","DOI":"10.1158\/1538-7445.AM2022-CT196"},{"issue":"10","key":"1737_CR196","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","volume":"27","author":"Y Hu","year":"2021","unstructured":"Hu Y, Zhou Y, Zhang M, Ge W, Li Y, Yang L, et al. CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2021;27(10):2764\u201372.","journal-title":"Clin Cancer Res"},{"key":"1737_CR197","doi-asserted-by":"crossref","unstructured":"Abramson JS, Ramakrishnan A, Pierola AA, Braunschweig I, Cartron G, Thieblemont C, et al. Preliminary Results of Nathali-01: A First-in-Human Phase I\/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R\/R) Non-Hodgkin Lymphoma (NHL). Blood. 2023;142(Supplement 1):2110-.","DOI":"10.1182\/blood-2023-186570"},{"issue":"Supplement 1","key":"1737_CR198","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1182\/blood-2023-187252","volume":"142","author":"N Jain","year":"2023","unstructured":"Jain N, Chevallier P, Liu H, Schiller GJ, M\u00e9ar J-B, DeAngelo DJ, et al. Updated results of the phase I BALLI-01 trial of UCART22 process 2 (P2), an anti-CD22 allogeneic CAR-T cell product manufactured by Cellectis Biologics, in patients with relapsed or refractory (R\/R) CD22+ B-cell acute lymphoblastic leukemia (B-ALL). Blood. 2023;142(Supplement 1):4847.","journal-title":"Blood"},{"issue":"S2","key":"1737_CR199","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/hon.3163_47","volume":"41","author":"CA Ramos","year":"2023","unstructured":"Ramos CA, Quach DH, Lulla PD, Rouce RH, Sharma S, Ganesh HR, et al. Off-the-shelf CD30.CAR-modified Epstein-Barr virus-specific T cells (CD30.CAR EBVSTs) provide a safe and effective therapy for patients with Hodgkin lymphoma (HL). Hematol Oncol. 2023;41(S2):83\u20135.","journal-title":"Hematol Oncol"},{"issue":"16","key":"1737_CR200","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhang M, Yang T, Mo Z, Wei G, Jing R, et al. Sequential CD7 CAR t-cell therapy and allogeneic HSCT without GVHD prophylaxis. N Engl J Med. 2024;390(16):1467\u201380.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"1737_CR201","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1182\/blood-2023-178723","volume":"142","author":"A Ghobadi","year":"2023","unstructured":"Ghobadi A, Aldoss I, Maude SL, Bhojwani D, Wayne AS, Bajel A, et al. Phase 1\/2 dose-escalation\/dose-expansion study of anti-CD7 allogeneic CAR-T cells (WU-CART-007) in relapsed or refractory (R\/R) T-cell acute lymphoblastic leukemia\/ lymphoblastic lymphoma (T-ALL\/LBL). Blood. 2023;142(Supplement 1):770.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1737_CR202","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1182\/blood-2022-170819","volume":"140","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Li C, Jiang H, Luo W, Du M, Zhou F, et al. Allogeneic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T cell malignancies. Blood. 2022;140(Supplement 1):4592\u20134.","journal-title":"Blood"},{"issue":"8","key":"1737_CR203","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","volume":"24","author":"CE Brown","year":"2022","unstructured":"Brown CE, Rodriguez A, Palmer J, Ostberg JR, Naranjo A, Wagner JR, et al. Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma. Neuro Oncol. 2022;24(8):1318\u201330.","journal-title":"Neuro Oncol"},{"issue":"3_suppl","key":"1737_CR204","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2021.39.3_suppl.74","volume":"39","author":"H Prenen","year":"2021","unstructured":"Prenen H, Dekervel J, Hendlisz A, Anguille S, Awada A, Cerf E, et al. Updated data from alloshrink phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC. J Clin Oncol. 2021;39(3_suppl):74.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1737_CR205","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1182\/blood-2021-146045","volume":"138","author":"LJ Lekakis","year":"2021","unstructured":"Lekakis LJ, Locke FL, Tees M, Neelapu SS, Malik SA, Hamadani M, et al. ALPHA2 study: ALLO-501A allogeneic CAR t in LBCL, updated results continue to show encouraging safety and efficacy with consolidation dosing. Blood. 2021;138(Supplement 1):649.","journal-title":"Blood"},{"key":"1737_CR206","doi-asserted-by":"crossref","unstructured":"Haag S, Eskew JD, McArthur K, McCaigue J, Vaziri S, DePrimo S, et al. Solid tumor patients require higher cyclophosphamide (cy) dose than multiple myeloma (MM) patients to achieve adequate lymphodepletion (LD) necessary to enable allogeneic CAR-T expansion. Cancer Research. 2024;84(7).","DOI":"10.1158\/1538-7445.AM2024-CT070"},{"issue":"19","key":"1737_CR207","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1182\/blood-2010-04-001230","volume":"116","author":"SM Jaglowski","year":"2010","unstructured":"Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood. 2010;116(19):3705\u201314.","journal-title":"Blood"},{"issue":"18","key":"1737_CR208","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","volume":"21","author":"CE Brown","year":"2015","unstructured":"Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, et al. Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21(18):4062\u201372.","journal-title":"Clin Cancer Res"},{"key":"1737_CR209","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/01.HS9.0000843940.96598.e2","volume":"6","author":"SP Iyer","year":"2022","unstructured":"Iyer SP, Sica RA, Ho PJ, Hu B, Zain J, Prica A, et al. THE COBALT-LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70-TARGETED ALLOGENEIC CRISPR-CAS9-ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED\/REFRACTORY (R\/R) TCELL MALIGNANCIES. HemaSphere. 2022;6:330\u20131.","journal-title":"HemaSphere"},{"issue":"7","key":"1737_CR210","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jcyt.2023.03.011","volume":"25","author":"E Lau","year":"2023","unstructured":"Lau E, Kwong G, Fowler TW, Sun BC, Donohoue PD, Davis RT, et al. Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness. Cytotherapy. 2023;25(7):750\u201362.","journal-title":"Cytotherapy"},{"key":"1737_CR211","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7025","author":"B Hu","year":"2024","unstructured":"Hu B, Nastoupil LJ, Holmes H, Hamdan A, Kanate A, Farooq U, et al. A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed\/refractory B cell non-Hodgkin lymphoma (r\/r B-NHL): updated phase 1 results from the ANTLER trial. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7025.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1737_CR212","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17(1):105.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1737_CR213","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","volume":"42","author":"U Uslu","year":"2024","unstructured":"Uslu U, Castelli S, June CH. CAR t cell combination therapies to treat cancer. Cancer Cell. 2024;42(8):1319\u201325.","journal-title":"Cancer Cell"},{"issue":"6","key":"1737_CR214","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.medj.2024.03.001","volume":"5","author":"J Liu","year":"2024","unstructured":"Liu J, Jiao X, Ma D, Fang Y, Gao Q. CAR-T therapy and targeted treatments: emerging combination strategies in solid tumors. Med. 2024;5(6):530\u201349.","journal-title":"Med"},{"key":"1737_CR215","doi-asserted-by":"crossref","unstructured":"Li Y, Liu S, Cui Q, Liu L, Li Z, Cui W, et al. Rituximab Improves Clinical Outcomes of CAR-T Therapy for r\/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion. Blood. 2023;142(Supplement 1):6803-.","DOI":"10.1182\/blood-2023-184505"},{"issue":"11","key":"1737_CR216","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29(11):2844\u201353.","journal-title":"Nat Med"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01737-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01737-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01737-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:03:01Z","timestamp":1768341781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-025-01737-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":216,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1737"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01737-8","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated to include an omitted funding acknowledgement.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}